Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

Health-care companies rose, as health insurers and other "middle men" recouped some of their recent losses. UnitedHealth Group, which has become the center of a public debate about health-care policy ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

U.S. stocks are rallying to more than halve their losses in what had been one of their worst weeks of the year. The S&P 500 ...

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after ...

In November, NVO shares crossed into a long-term bear market as they fell below their 20-month moving average - a key ...

Novo Nordisk faces scrutiny after disappointing trial results for CagriSema, a next-gen obesity drug, caused a significant market valuation drop. Analysts question whether side effects limited dosage ...

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers ...